Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from MicroPort NeuroTech Limited ( (HK:2172) ) is now available.
MicroPort NeuroTech Limited reported a strong financial performance for the year ended December 31, 2024, with a 14.4% increase in revenue to RMB761.8 million and an 84.9% rise in net profit to RMB248.9 million. This growth was driven by breakthroughs in overseas markets, increased market share of cerebral atherosclerotic stenosis products, successful VBP bids for coil products, and the accelerated adoption of acute ischemic stroke products. The company also achieved a 44.2% increase in non-HKFRS adjusted net profit, leading to a recommended final dividend of HK$0.11 per share.
More about MicroPort NeuroTech Limited
MicroPort NeuroTech Limited operates in the medical technology industry, focusing on products for neurological disorders. The company specializes in hemorrhagic stroke products, cerebral atherosclerotic stenosis products, acute ischemic stroke products, and access products, with a significant market presence both domestically and internationally.
YTD Price Performance: 41.46%
Average Trading Volume: 4,286,536
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$7.35B
For a thorough assessment of 2172 stock, go to TipRanks’ Stock Analysis page.